NASD · Healthcare · Healthcare Plans · USA
Progyny Inc is a mid cap company (market value between $2 billion and $10 billion) in the Healthcare Plans industry.
Progyny provides women's health and family building benefits solutions to employers. The company offers fertility benefits through its Smart Cycle approach, pregnancy and postpartum support, menopause services, pharmacy solutions, and parent and child wellbeing programs. Progyny serves employer clients covering employees and dependents through its network of fertility specialists and integrated support services.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Progyny Inc stock.
Slightly overvalued: intrinsic value $23.50 per share, market price $27.84, margin of safety -18.5% (as of 2026-10-19).
Discounting its cash flows at 9.9% (average of 3 methods) values the shares at $23.50; the price of $27.84 is 18% above that value, and 75% of that value comes from beyond year five.
Leak Score: 74/100 on 11 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
All 11 Healthcare Plans stocks
2 more in this industry show a wider margin of safety.
PGNY is slightly overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.9% (average of 3 methods) values the shares at $23.50; the price of $27.84 is 18% above that value, and 75% of that value comes from beyond year five.
$23.50 per share (as of the 2026-10-19 close), against a market price of $27.84. That is a margin of safety of -18.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
74 out of 100, which we rate "Clear Leak", on 11 of 12 value investing signals.